Mr. Bohlin has served as a member of our board of directors since October 2013. Mr. Bohlin was Executive Vice President of Constellation Pharmaceuticals. Previously, he served as Chief Operating Officer of Sirtris Pharmaceuticals, which was acquired by GlaxoSmithKline. Prior to Sirtris, he was President and Chief Executive Officer of Syntonix Pharmaceuticals, which was acquired by Biogen Idec. Prior to Syntonix, he was Executive Vice President of Genetics Institute, which was acquired by American Home Products/Wyeth. Mr. Bohlin played a key strategic role in each of his positions and also had substantial operational experience. Mr. Bohlin currently serves on the board of directors of Collegium Pharmaceutical, Inc., Proteon Therapeutics, Inc. and Tetraphase Pharmaceuticals, Inc.
Mikael Dolsten, MD, PhD
Dr. Dolsten has served as a member of our board of directors since March 2015. He has served as the President of Worldwide Research and Development and Medical and Executive Vice President of Pfizer Inc., a biopharmaceutical company, since December 2010. Dr. Dolsten served as President of Worldwide Research and Development and Senior Vice President of Pfizer Inc. from May 2010 until December 2010 and President of Pfizer BioTherapeutics Research & Development Group and Senior Vice President of Pfizer Inc. from October 2009 until May 2010. From June 2008 to October 2009, Dr. Dolsten served as Senior Vice President of Wyeth, a biopharmaceutical company that was acquired by Pfizer Inc. in October 2009, and President, Wyeth Research from June 2008 to October 2009. Prior to joining Wyeth, Dr. Dolsten was a Private Equity Partner at Orbimed Advisors, LLC and Executive Vice President, Head of Pharma Research at Boehringer Ingelheim, a pharmaceutical company. Dr. Dolsten also previously held research leadership positions at AstraZeneca, Pharmacia and Upjohn. He is widely recognized as a leader within the medical research and drug development community.
Scott Garland, MBA
Mr. Garland has served as a member of our board of directors since November 2014. Mr. Garland is currently President and Chief Executive Officer and a member of the board of directors of Portola Pharmaceuticals, Inc. a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics targeting thrombosis and other hematologic diseases. Prior to joining Portola in 2018, Mr. Garland was President and previously Chief Commercial Officer at Relypsa Inc. Prior to Relypsa, Mr. Garland served as Executive Vice President and Chief Commercial Officer of Exelixis, Inc. a biopharmaceutical company focused on developing and commercializing cancer treatments, from October 2011 to October 2014. Prior to joining Exelixis, Mr. Garland spent close to a decade at Genentech leading the commercial franchises for two multi-billion dollar therapies – Avastin® (bevacizumab) and Rituxan® (rituximab). He started his career at Merck as a sales representative and then went on to serve at Amgen in various sales and marketing roles, including market development, to support the launch of Aranesp® (darbepoetin alfa). Mr. Garland has an M.B.A. from Duke University’s Fuqua School of Business and a B.A. from California Polytechnic University (San Luis Obispo).
Barry E. Greene
Mr. Greene has served as a member of our board of directors since January 2013 and as our lead independent director since January 2015. Mr. Greene has served as President and Chief Operating Officer of Alnylam Pharmaceuticals, Inc., a public biopharmaceutical company, since 2007, as its Chief Operating Officer since 2003, and from 2004 through 2005, as its Treasurer. Mr. Greene joined Alnylam in 2003, bringing over 15 years of experience in the healthcare industry and in consulting. Prior to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals, Inc., a biopharmaceutical company, where he led the company’s global strategy and execution for its oncology business, including strategic business direction and execution, culminating in the successful FDA approval and launch of VELCADE (bortezomib) in mid-2003.
Prior to joining Millennium in 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com, a healthcare consulting company. Prior to Mediconsult.com, Mr. Greene’s experience included serving as Vice President of Marketing and Customer Services for AstraZeneca (formerly AstraMerck), a biopharmaceutical company; Vice President, Strategic Integration with responsibility for the AstraZeneca North American post-merger integration; and a partner of Andersen Consulting, a consulting company, where he was responsible for the pharmaceutical/biotechnology marketing and sales practice. Mr. Greene currently is a member of the board of directors of Acorda Therapeutics, Inc., a public biopharmaceutical company. Mr. Greene received his B.S. in Industrial Engineering from the University of Pittsburgh and served as a Senior Scholar at Duke University, Fuqua School of Business.
Mansoor Raza Mirza, MD
Dr. Mirza has served as a member of our board of directors since October 2010. He has also served as a scientific consultant to us since 2010. Dr. Mirza is Chief Oncologist at the Department of Oncology, Rigshopitalet — the Copenhagen University Hospital, Denmark and Medical Director of Nordic Society of Gynaecological Oncology (NSGO).
Dr. Mirza is both a medical and radiation oncologist, with a primary focus in non-surgical treatment of gynecologic cancers. His key academic goals are to promote clinical research, international trial collaboration and education, and he has broad experience in clinical protocol development, trial conduct and clinical trial regulations.
Dr. Mirza is the author of several phase 1, 2 and 3 studies and serves as the chair of the Independent Data Safety Monitoring Committee of the OUTBACK trial, which is a large international cervical cancer trial. He is the senior author of national Danish guidelines for the management of endometrial, cervical, vulvar and non-epithelial ovarian cancers as well as of NSGO radio therapy guidelines for cervical and vulvar cancers.
His other current appointments include service as ESGO Council Member (European Society of Gynaecological Oncology), Executive Director of GCIG (Gynecologic Cancer InterGroup), Vice-Chairman of the Danish Gynecological Cancer Society, Founding Executive Member of the European Network of Gynecologic Oncology Trials Group and faculty member of the European Society of Medical Oncology and of the International Gynecologic Cancer Society. He also serves on the board of directors of Sera Prognostics, Inc., a private biopharmaceutical company.
He holds a M.D., Diploma in Surgery and Diploma in Clinical Oncology from the Pirogov Moscow State Medical Institute as well as post-graduate education and certification in radiation and medical oncology from the University of Southern Denmark.
Deepa R. Pakianathan, PhD
Dr. Pakianathan has served as a member of our board of directors since April 2013. Since 2001, Dr. Pakianathan has been a Managing Member at Delphi Ventures, a venture capital firm focused on medical device and biotechnology investments, and leads the firm’s biotechnology investment activities. From 1998 to 2001, Dr. Pakianathan was a senior biotechnology banker at JPMorgan, a global investment bank. Dr. Pakianathan currently serves on the board of directors of Calithera Biosciences, Inc., a public biopharmaceutical company.
Dr. Pakianathan received a B.Sc. from the University of Bombay, India, a M.Sc. from The Cancer Research Institute at the University of Bombay, India, and an M.S. and Ph.D. from Wake Forest University.
Michael G. Kauffman , MD, PhD
Director, Chief Executive Officer
Dr. Kauffman co-founded Karyopharm with Dr. Sharon Shacham in 2008 and has served as our Chief Executive Officer since January 2011, as Chief Medical Officer since December 2012, and as a director since 2008. Prior to joining Karyopharm, Dr. Kauffman served as Chief Medical Officer at Onyx Pharmaceuticals Inc., which acquired Proteolix Inc. in November 2009 where he was Chief Medical Officer and where he led the development of Kyprolis® (carfilzomib), a novel proteasome inhibitor which was approved by the FDA for the treatment of refractory myeloma in 2012.
Prior to joining Onyx, Dr. Kauffman was an operating partner at Bessemer Venture Partners where he led investments in biotechnology companies. Prior to that, he served as President and Chief Executive Officer at Epix Pharmaceuticals, Inc. and President and Chief Executive Officer of Predix Pharmaceuticals, Inc. Dr. Kauffman led the merger of Predix Pharmaceuticals and Epix Pharmaceuticals in 2006, oversaw the discovery and development of four new clinical candidates, and led collaboration transactions with Amgen and GlaxoSmithKline.
From 2000 to 2002, Dr. Kauffman was Vice President, Clinical at Millennium Pharmaceuticals, Inc., where he led the Velcade® (bortezomib) development program. From 1997 to 2000, Dr. Kauffman served in senior leadership roles at Millennium Predictive Medicine, Inc., a subsidiary of Millennium Pharmaceuticals, where he led the discovery and development of novel molecular diagnostics for major cancers including melanoma, and led transactions with Becton-Dickenson and Bristol Myers Squibb. From 1995 to 1997, he held a number of senior positions at Biogen Idec, Inc., where he led the clinical development of anti-D40L antibodies in autoimmune and inflammatory diseases, and acted as the main medical advisor to the Biogen business development group. Dr. Kauffman currently serves on the board of directors of Infinity Pharmaceuticals, Inc., Kezar Life Sciences, Inc. and Verastem Inc., which are all public biopharmaceutical companies.
Dr. Kauffman received his Bachelor of Arts in Biochemistry from Amherst College, his Doctor of Medicine and Doctor of Philosophy from Johns Hopkins Medical School, and trained in internal medicine and rheumatology at Beth Israel (now Beth Israel Deaconness Medical Center) and Massachusetts General Hospitals. He is board certified in internal medicine.